Medivation Reports Third Quarter Financial Results and Provides Corporate Update

Medivation Reports Third Quarter Financial Results and Provides Corporate Update 
$60.0 Million in Revenue Driven by $108.5 Million in Third Quarter
U.S. Net Sales of XTANDI; Conference Call Today at 4:30 p.m. Eastern
Time 
SAN FRANCISCO, CA -- (Marketwired) -- 11/12/13 --  Medivation, Inc.
(NASDAQ: MDVN) today provided a corporate update and reported its
financial results for the third quarter ended September 30, 2013.
U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter,
as reported by Astellas Pharma Inc., were $108.5 million. Ex-U.S. net
sales of XTANDI for the quarter, as reported by Astellas, were $13.0
million. XTANDI was granted marketing authorization in the European
Union in June 2013. 
"The strong demand that we've seen for XTANDI, coupled with the
positive results from our Phase 3 PREVAIL study, places us in a
strong position as we look to advance to the next chapter in our
company's development," said David Hung, M.D., president and chief
executive officer of Medivation, Inc. "The robust results from our
PREVAIL trial, in which enzalutamide demonstrated a 30% reduction in
risk of death and a 81% reduction in the risk of radiographic
progression or death compared with placebo, enables us to pursue a
number of regulatory, commercial and clinical milestones in the
months and years ahead."  
Recent Developments  
XTANDI(R) (enzalutamide) capsules 


 
--  U.S. net sales of XTANDI were $108.5 million in the third quarter of
    2013. XTANDI was approved by the U.S. Food and Drug Administration for
    the treatment of patients with metastatic castration-resistant
    prostate cancer (mCRPC) who have previously received docetaxel on
    August 31, 2012 and was made available for shipment on September 13,
    2012. Medivation and Astellas are jointly responsible for
    commercialization and development of XTANDI in the U.S. and share
    equally in the costs (subject to certain exceptions), profits and
    losses arising from U.S. development and commercialization of XTANDI.
    
    
--  Ex-U.S. net sales of XTANDI were $13.0 million in the third quarter of
    2013. XTANDI was granted marketing authorization in the European Union
    in June 2013. Outside of the U.S., Astellas has responsibility for
    developing and commercializing XTANDI and pays Medivation a tiered
    royalty ranging from the low teens to the low twenties on aggregate
    net sales of XTANDI.
    
    
--  XTANDI is now available in approximately 12 countries with filings
    underway in 35 countries around the world.

  
PREVAIL 


 
--  Announced the results of a planned interim analysis of the global
    Phase 3 PREVAIL trial of enzalutamide in more than 1,700 men with
    metastatic prostate cancer that has progressed despite androgen
    deprivation therapy and who have not yet received chemotherapy. The
    Independent Data Monitoring Committee (IDMC) informed Medivation and
    Astellas of the following results:
    
    
    --  Patients treated with enzalutamide demonstrated a statistically
        significant overall survival advantage compared with patients
        receiving placebo (p
        
    --  Patients treated with enzalutamide demonstrated a statistically
        significant radiographic progression-free survival advantage
        compared with patients receiving placebo (p
        
    --  Given the overall survival benefit and the observed safety
        profile, the IDMC considered the overall benefit-risk ratio to
        favor the enzalutamide arm and recommended unequivocally that
        patients receiving placebo be offered treatment with
        enzalutamide.
        
        
--  Of the 1,715 patients treated in the blinded PREVAIL study, two
    patients were reported by investigators to have had a seizure event.
    The full analysis of the safety data will become available upon final
    database lock and unblinding.
    
    
--  Medivation and Astellas will initiate meetings with and submissions to
    regulatory agencies beginning in early 2014. A full analysis of the
    Phase 3 PREVAIL results, including safety data, will be submitted for
    presentation at an upcoming scientific conference.

  
Enzalutamide Clinical Development Program 


 
--  Initiated a Phase 4 clinical trial, known as PLATO. The study will
    evaluate the efficacy and safety of continued treatment with
    enzalutamide plus abiraterone acetate and prednisone as compared to
    treatment with abiraterone acetate and prednisone alone in patients
    with chemotherapy-naive metastatic prostate cancer whose disease
    has progressed following enzalutamide therapy. The purpose of the
    trial is to help determine the potential clinical benefit of extending
    time on enzalutamide treatment by adding an additional therapy in
    patients with progressive chemotherapy-naive metastatic prostate
    cancer. The global randomized, double-blind, placebo-controlled trial
    is designed to enroll approximately 500 chemotherapy-naive
    patients with mCRPC. The primary endpoint of the trial is
    progression-free survival.
    
    
--  Advanced the development program comparing enzalutamide's effects on
    progression-free-survival when compared head-to-head versus
    bicalutamide, the most commonly used anti-androgen, in men who have
    progressed following medical castration with LHRH analog therapy or
    surgical castration.
    
    
    --  Completed patient enrollment in the TERRAIN trial in July 2013,
        which enrolled approximately 370 men with mCRPC disease primarily
        in Europe; and
        
        
    --  Continued patient enrollment in the STRIVE trial, which is
        enrolling approximately 400 men with either metastatic or
        non-metastatic disease primarily in the U.S.
        
        
--  Continued patient enrollment in a Phase 2 clinical trial evaluating
    enzalutamide as a single agent for the treatment of advanced, androgen
    receptor (AR)-positive, triple-negative breast cancer (TNBC). The
    Phase 2 open label, single-arm, multicenter trial plans to enroll
    approximately 80 patients with AR-positive, TNBC at sites in the
    United States, Canada and Europe. The primary endpoint of the trial is
    clinical benefit rate, defined as the proportion of patients with a
    best response of complete response, partial response or stable disease
    at ≥ 16 weeks.

  
Third Quarter Financial Results 
XTANDI U.S. net sales for the third quarter of 2013, as reported by
Astellas, were $108.5 million compared to $82.4 million in the second
quarter of 2013. Ex-U.S. net sales of XTANDI, as reported by
Astellas, were $13.0 million in the third quarter of 2013 compared to
$3.7 million in the second quarter of 2013. Medivation's
collaboration revenue was $60.0 million for the third quarter of
2013, which consists of three components: collaboration revenue
attributable to U.S. XTANDI net sales ($54.2 million), collaboration
revenue attributable to ex-U.S. XTANDI sales ($1.6 million) and
collaboration revenue attributable to up-front and development
milestone payments ($4.2 million).  
Total operating expenses for the quarter ended September 30, 2013
were $68.0 million, compared with total operating expenses of $64.4
million for the same period in 2012. These figures include non-cash
stock-based compensation expense of $9.2 million in the quarter ended
September 30, 2013, compared with $7.6 million for the same period in
2012. 
Medivation reported a net loss of $13.3 million, or $0.18 per diluted
share, for the quarter ended September 30, 2013, compared with a net
loss of $4.5 million, or $0.06 per diluted share, for the same period
in 2012.  
At September 30, 2013, cash, cash equivalents and short-term
investments totaled $243.0 million, compared with $296.2 million at
December 31, 2012.  
2013 Financial Outlook 
For the full year 2013, Medivation expects U.S. net sales of XTANDI,
as reported by Astellas, to exceed its prior guidance of $345-365
million. Medivation continues to expect total operating expenses, net
of cost-sharing payments from Astellas, to be between $285 million
and $300 million.  
Conference Call Information 
To participate by telephone in today's live call beginning at 4:30
p.m. Eastern Time, please call 877-303-2523 from the U.S. or
+1-253-237-1755 internationally. Individuals may access the live
audio webcast by visiting http://investors.medivation.com/events.cfm.
A replay of the webcast will be available on the Company's website
for a limited time following the live event. 
About XTANDI(R) (enzalutamide) capsules  
XTANDI was approved by the FDA on August 31, 2012 and is indicated
for the treatment of patients with metastatic castration-resistant
prostate cancer (mCRPC) who have previously received docetaxel. 
Important Safety Information for XTANDI from the Approved Prescribing
Information  
Contraindications- XTANDI can cause fetal harm when administered to a
pregnant woman based on its mechanism of action. XTANDI is not
indicated for use in women. XTANDI is contraindicated in women who
are or may become pregnant.  
Warnings and Precautions- In the randomized clinical trial, seizure
occurred in 0.9% of patients on XTANDI. No patients on the placebo
arm experienced seizure. Patients experiencing a seizure were
permanently discontinued from therapy. All seizures resolved.
Patients with a history of seizure, taking medications known to
decrease the seizure threshold, or with other risk factors for
seizure were excluded from the clinical trial. Because of the risk of
seizure associated with XTANDI use, patients should be advised of the
risk of engaging in any activity where sudden loss of consciousness
could cause serious harm to themselves or others.  
Adverse Reactions- The most common adverse drug reactions ( ≥
5%) reported in patients receiving XTANDI in the randomized clinical
trial were asthenia/fatigue, back pain, diarrhea, arthralgia, hot
flush, peripheral edema, musculoskeletal pain, headache, upper
respiratory infection, muscular weakness, dizziness, insomnia, lower
respiratory infection, spinal cord compression and cauda equina
syndrome, hematuria, paresthesia, anxiety, and hypertension.  
Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1% Grade
3-4) and in 6% on placebo (no Grade 3-4). Grade 1-4 elevations in
bilirubin occurred in 3% of XTANDI patients and 2% on placebo. One
percent of XTANDI patients compared to 0.3% on placebo died from
infections or sepsis. Falls or injuries related to falls occurred in
4.6% of XTANDI patients vs 1.3% on placebo. Falls were not associated
with loss of consciousness or seizure. Fall-related injuries were
more severe in XTANDI patients and included non-pathologic fractures,
joint injuries, and hematomas. Grade 1 or 2 hallucinations occurred
in 1.6% of XTANDI patients and 0.3% on placebo, with the majority on
opioid-containing medications at the time of the event.  
Drug Interactions- Effect of Other Drugs on XTANDI: Administration of
strong CYP2C8 inhibitors can increase the plasma exposure to XTANDI.
Co-administration of XTANDI with strong CYP2C8 inhibitors should be
avoided if possible. If co-administration of XTANDI cannot be
avoided, reduce the dose of XTANDI. Co-administration of XTANDI with
strong or moderate CYP3A4 and CYP2C8 inducers can alter the plasma
exposure of XTANDI and should be avoided if possible.  
Effect of XTANDI on Other Drugs: XTANDI is a strong CYP3A4 inducer
and a moderate CYP2C9 and CYP2C19 inducer in humans. Avoid CYP3A4,
CYP2C9 and CYP2C19 substrates with a narrow therapeutic index, as
XTANDI may decrease the plasma exposures of these drugs. If XTANDI is
co-administered with warfarin (CYP2C9 substrate), conduct additional
INR monitoring.  
Please visit www.XtandiHCP.com for full Prescribing Information for
XTANDI(R) (enzalutamide) capsules.  
About Medivation  
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients
and their families. For more information, please visit us at
http://www.medivation.com. 
Forward-Looking Statements 
The statements in this press release under the caption "2013
Financial Outlook" are forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities
laws. Forward-looking statements involve risks and uncertainties that
could cause Medivation's actual results to differ significantly from
those projected, including, without limitation: risks related to the
timing, progress and results of Medivation's clinical trials,
including the risk that adverse clinical trial results could alone or
together with other factors result in the delay or discontinuation of
the commercialization of XTANDI or some or all of Medivation's
product development activities; Medivation's dependence on the
efforts of and funding by Astellas for the commercialization of
XTANDI; the risk of unanticipated expenditures or liabilities; and
other risks detailed in Medivation's filings with the Securities and
Exchange Commission, or SEC, including its quarterly report on Form
10-Q for the quarter ended September 30, 2013, which is expected to
be filed on November 12, 2013 with the SEC. You are cautioned not to
place undue reliance on the forward-looking statements, which speak
only as of the date of this release. Medivation disclaims any
obligation or undertaking to update, supplement or revise any
forward-looking statements contained in this press release. 


 
                                                                            
                                                                            
                              MEDIVATION, INC.                              
                                                                            
                        CONSOLIDATED BALANCE SHEETS                         
              (in thousands, except share and per share data)               
                                (unaudited)                                 
                                                                            
                                              September 30,   December 31,  
                                                  2013            2012      
                                             --------------  -------------- 
ASSETS                                                                      
Current assets:                                                             
  Cash and cash equivalents                  $      157,968  $       71,301 
  Short-term investments                             84,998         224,939 
 
  Receivable from collaboration partner              67,584          35,458 
  Restricted cash                                         -             343 
  Prepaid expenses and other current assets          17,341          12,175 
                                             --------------  -------------- 
                                                                            
    Total current assets                            327,891         344,216 
Property and equipment, net                          17,097          13,262 
Restricted cash, net of current                       9,899           8,843 
Other non-current assets                              6,155           5,545 
                                             --------------  -------------- 
                                                                            
Total assets                                 $      361,042  $      371,866 
                                             ==============  ============== 
                                                                            
LIABILITIES AND STOCKHOLDERS' EQUITY                                        
Current liabilities:                                                        
  Accounts payable                           $        5,474  $        2,073 
  Accrued expenses and other current                                        
   liabilities                                       61,755          48,951 
  Deferred revenue                                   16,931          33,862 
                                             --------------  -------------- 
                                                                            
    Total current liabilities                        84,160          84,886 
Convertible Notes, net of unamortized                                       
 discount of $53,577 and $62,743 at                                         
 September 30, 2013 and December 31, 2012,                                  
 respectively                                       205,173         196,007 
Deferred revenue, net of current                      4,233           8,465 
Other non-current liabilities                         7,140           8,863 
                                             --------------  -------------- 
                                                                            
    Total liabilities                               300,706         298,221 
Commitments and contingencies                                               
Stockholders' equity:                                                       
  Preferred stock, $0.01 par value per                                      
   share; 1,000,000 shares authorized; no                                   
   shares issued and outstanding                          -               - 
  Common stock, $0.01 par value per share;                                  
   170,000,000 shares authorized; 75,344,784                                
   and 74,774,939 shares issued and                                         
   outstanding at September 30, 2013 and                                    
   December 31, 2012, respectively                      754             748 
  Additional paid-in capital                        396,493         364,412 
  Accumulated other comprehensive income                 18              33 
  Accumulated deficit                              (336,929)       (291,548)
                                             --------------  -------------- 
                                                                            
    Total stockholders' equity                       60,336          73,645 
                                             --------------  -------------- 
                                                                            
Total liabilities and stockholders' equity   $      361,042  $      371,866 
                                             ==============  ============== 
                                                                            
                                                                            
                                                                            
                                                                            
                              MEDIVATION, INC.                              
                                                                            
                   CONSOLIDATED STATEMENTS OF OPERATIONS                    
                   (in thousands, except per share data)                    
                                (unaudited)                                 
                                                                            
                                     Three Months Ended   Nine Months Ended 
                                        September 30,       September 30,   
                                     ------------------  ------------------ 
                                       2013      2012      2013      2012   
                                     --------  --------  --------  -------- 
Collaboration revenue                $ 60,027  $ 64,798  $176,330  $144,535 
Operating expenses:                                                         
  Research and development expenses    28,737    32,045    81,850    73,625 
  Selling, general and                                                      
   administrative expenses             39,288    32,345   124,746    70,369 
                                     --------  --------  --------  -------- 
                                                                            
    Total operating expenses           68,025    64,390   206,596   143,994 
                                     --------  --------  --------  -------- 
                                                                            
Income (loss) from operations          (7,998)      408   (30,266)      541 
Other income (expense), net:                                                
  Interest expense                     (5,165)   (4,840)  (15,035)  (10,113)
  Interest income                          40        57       166       140 
  Other expense, net                     (132)     (154)     (123)     (169)
                                     --------  --------  --------  -------- 
                                                                            
    Total other income (expense),                                           
     net                               (5,257)   (4,937)  (14,992)  (10,142)
                                     --------  --------  --------  -------- 
                                                                            
Net loss before income tax (expense)                                        
 benefit                              (13,255)   (4,529)  (45,258)   (9,601)
Income tax (expense) benefit              (58)       (8)     (123)        4 
                                     --------  --------  --------  -------- 
                                                                            
Net loss                             $(13,313) $ (4,537) $(45,381) $ (9,597)
                                     ========  ========  ========  ======== 
Basic and diluted net loss per                                              
 common share                        $  (0.18) $  (0.06) $  (0.60) $  (0.13)
                                     ========  ========  ========  ======== 
Weighted average common shares used                                         
 in the calculation of basic and                                            
 diluted net loss per common share     75,255    73,697    75,032    72,794 
                                     ========  ========  ========  ======== 

  
Contacts:
Patrick Machado 
Chief Business & Financial Officer 
(41
5) 829-4101 
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900 
 
 
Press spacebar to pause and continue. Press esc to stop.